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Background: Despite the excellent results obtained with hormone therapy, the long treatment period and the side
effects associated with its use make patient adherence difficult. Moreover, certain aspects of health care can
mitigate or exacerbate non-adherence. This study aimed to identify the factors associated with adherence to
hormone therapy for breast cancer, with the goal of contributing to the reformulation of the care process and to
improvements in outcomes.
Method: This was a retrospective longitudinal study based on secondary data. The study integrated and analyzed
data from a cohort of 5,861 women with breast cancer who were identified in the databases of the Brazilian
National Cancer Institute [Instituto Nacional de Câncer - INCA] and the Unified Health System [Sistema Único de
Saúde - SUS]. All of the patients were treated at INCA, which dispenses free medication, and the follow-up period
lasted from 01/01/2004 to 10/29/2010. The outcome of interest was hormone treatment adherence, which was defined
as the possession of medication, and a logistic regression model was employed to identify the socio-demographic,
behavioral, clinical, and health care variables that were independently associated with the variations in this outcome.
Results: The proportion of women who adhered to hormone therapy was 76.3%. The likelihood of adherence to
hormone therapy increased with each additional year of age, as well as among women with a secondary or higher
level education, those with a partner, those who underwent surgery, those who had more consultations with a breast
specialist and clinical oncologist, and those who underwent psychotherapy; the effect for the latter increased with
each additional consultation. Conversely, the likelihood of adherence was lower among patients at a non-curable stage,
those who were alcohol drinkers, those who received chemotherapy, those who had undergone more tests and had
more hospitalizations, and those who used tamoxifen and combined aromatase inhibitors.
Conclusion: This study shows that approximately a quarter of the women with breast cancer did not adhere to
hormone treatment, thus risking clinical responses below the expected standards. It also identifies the most vulnerable
subgroups in the treatment process and the aspects of care that provide better results.
Keywords: Breast cancer, Adherence, Hormone therapy, Tamoxifen, Aromatase inhibitors, Organization of care, Risk
factors, Health care organization, Quality of health careBackground
Studies of endocrine therapy for breast cancer treatment
have been increasingly performed throughout the world
[1] due to the large patient volume [2], the long treatment
duration [3], the optimal obtained results [4,5], and the
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reproduction in any medium, provided the orAdjuvant endocrine therapy or hormone therapy for breast
cancer involves the use of hormone suppressants or similar
substances to inhibit tumor growth [7]. This type of ther-
apy is associated with lower rates of disease recurrence
and metastasis and, thus, improves mortality rates and
disease-free survival [4,8]. Consequently, its use and related
expenses have increased significantly in recent decades [2].
The duration of hormone treatment is relatively long,
and patients are required to use the medication daily for
5 years [3] to obtain the maximum benefits [9]. The in-
crease in oral medication use has highlighted a potentiald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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health and economic terms. If patients do not take their
medications, they will not benefit from them, thus
resulting in increased mortality and morbidity as well as
increased costs and consumption of care resources.
Moreover, if the doctor is unaware of the patient’s non-
adherence to oral therapy, he/she might attribute the
disease progression to the ineffectiveness of the drug
and change the regimen unnecessarily [10] or prescribe
a second- or third-line medicine with greater side effects
or costs. In Brazil, breast cancer is the leading cause of
cancer deaths among women (12,852 deaths in 2010),
and it is estimated that in 2013, 52,680 women will be
diagnosed with this type of tumor [11].
Despite the excellent results obtained with hormone
therapy, the long treatment period and the side effects
associated with its use make patient adherence difficult,
which can lead to adverse clinical outcomes [12,13]. More-
over, certain aspects of health care (e.g., the doctor-patient
relationship and the management of side effects) can miti-
gate or exacerbate non-adherence [1,8], even for patients
with a good prognosis [14,15].
This study aimed to identify the factors associated with
adherence to hormone therapy for breast cancer, with
the goal of contributing to the reformulation of the care
process and to improved outcomes.
Methods
A hospital-based population retrospective longitudinal
study was conducted with secondary data from women
with breast cancer who received hormone therapy prescrip-
tions from the National Cancer Institute (Instituto Nacional
de Câncer; INCA) of Brazil.
INCA is the Ministry of Health reference center for
cancer policies and care [16] and as such, INCA inte-
grates the public health system and provides all inpatient
and outpatient oncological treatment modalities free of
charge. It is also the largest breast cancer care provider
in the state of Rio de Janeiro, which has the highest inci-
dence of this disease in Brazil [11].
The study included all women with breast cancer who
appeared in the hospital-based cancer registry (hospital-
based cancer registry; RHC) between 2002 and 2008
who started hormone treatment with tamoxifen (TMX)
and/or the aromatase inhibitors (AIS) letrozole or anastro-
zole on or after 01/01/2004, and who received dispensed
medication more than once before 10/29/2010, according
to the INCA pharmacy (the only medicine dispensary for
those women).
An integration and analysis of the information found
in the following databases was performed as follows:
a. The dispensing database from the INCA pharmacy
aggregated data about medicine dispensation,including the date, type (TMX, letrozole and
anastrozole) and quantity. It permitted the
acquisition and delivery control of medicine with
satisfactory accuracy. Only patients who started
hormone therapy after 01/01/2004 were considered
because this database was established in October
2003 and thus included patients who required
continuous treatment. The last included dispensing
date was 10/29/2010.
b. The RHC database was implemented at INCA
according to the recommendations of the
International Agency for Research on Cancer
(IARC) and was employed in the study to obtain
sociodemographic and clinical variables.
The study inclusion criteria for women with breast
cancer tumors who were enrolled between 2002 and
2008 relied on data availability at the time of the
study. The RHC was organized by tumor, which
meant that a single patient with more than 1
primary malignant tumor (excluding recurrence or
metastasis) could be registered more than once. For
patients with multiple recorded tumors, we used the
more complete observation, the observation with
the highest stage if the diagnosis dates were the
same or the earliest observation if the diagnosis
dates were different.
c. The Integrated Hospital System (Sistema Hospitalar
Integrado; SHI) and the INCA Absolute System
databases were used to record the procedures
provided to women with breast cancer. The SHI was
established in 1998 and was used at INCA until
2004, at which time it was replaced by the Absolute
system. We evaluated data from 01/01/2002 to
10/29/2010. The Absolute system had more data
categories than the SHI and thus required data
cleaning to make the records compatible. The
option for the use of both SHI and Absolute as
sources of health care variables relied on their
comprehensiveness; this was in contrast to RHC,
which only included data concerning chemotherapy,
radiotherapy, and oncological surgery.
After combining the databases, the differences in dates
between the beginning of hormone treatment and the
diagnosis of breast cancer were calculated. There were
198 cases with negative values; these were most likely
due to typographical errors, and the data were subse-
quently corrected according to the following procedures.
(1) If the initial hormone treatment date was ≤ 3 months
earlier than the date of diagnosis, the diagnosis and the
initiation of hormone treatment were assumed to coin-
cide (i.e., the difference was equal to 0). (2) If the nega-
tive difference between the start of hormone therapy
and the diagnosis was > 3 months, and if the second
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nosis date, the first dispensing date was ignored and re-
placed with the second date, and the amount dispensed
on the discarded date was deducted from the total. With
these procedures, it was possible to retain 185 cases in
the analysis; however, 13 women were eliminated due to
a complete lack of consistency in the data.
Thus, data for 5,861 women were retained for analysis
in the integrated database. There was no systematic as-
sociation between the excluded cases and the variables
of interest; thus, there is a low probability that data ex-
clusion due to operational issues might have introduced
bias into the study.
Adherence is defined as the extent to which a patient
acts in accordance with the prescribed interval and dose
of a dosing regimen, and is operationalized, in a retro-
spective assessment, as the number of doses dispensed
in relation to the dispensing period, often called the
“medication possession ratio (MPR)” [12,17-19].
It was calculated, for each woman, by summing up all
quantities dispensed, and dividing the sum by her time
in the cohort, that, in turn, was given by the difference
between the last and the first dispensing date summed
to the last dispensed quantity, for those that did not die,
and between the death and the first dispensing date, for
those that died [12,17-19]. We considered the recom-
mendation of a daily hormone therapy (HT) pill for five
years. The drugs that INCA dispensed free of charge
were TMX and AIS.
Patients with an MPR ≥ 80% were considered adherent,
which is a criterion widely applied [20-22].
The independent variables of interest included socio-
demographic variables (RHC) such as the age at diagnosis,
education, and marital status; clinical variables (RHC)
such as the histological tumor type, stage, laterality, fam-
ily history of cancer, smoking, and alcohol consumption; and
treatment and health care variables (SHI/Absolute). The
latter included the type of hormone therapy (e.g., TMX
only, AIS only, letrozole or anastrozole, or both TMX and
AIS, which indicated a switch from one form of therapy to
the other), surgery, chemotherapy (CT), radiation therapy
(RT), hospitalizations, clinical consultations with mastolo-
gists, clinical oncologists and other doctors, psychotherapy,
multi-professional therapeutic support (MTS) (including
nursing ambulatory care, nutrition services, physical ther-
apy, speech therapy and psychology), services from a social
worker, dentist or pharmacist, diagnostic and therapeutic
services (DTS), and the time between the diagnosis and
the initiation of hormone treatment.
Bivariate analyses of adherence were conducted with
the chi-squared (χ2) test for categorical independent var-
iables and Student’s t-test for continuous variables.
Multivariate logistic regression was also used, while ex-
cluding variables without independent effects (p ≥ 0.15)for parsimoniousness. The analyses were performed with
the SAS® statistical software package, version 9.1 (SAS
Institute Inc., 2003; Cary, NC, USA).
The study was approved by the Research Ethics Committee
of INCA under number 84/2010.
Results
The patient age at diagnosis ranged from 21 to 103 years,
with a mean of 57.5 (SD = 13.6) years and a median of
56.6 years. Approximately 50% of the women were be-
tween 40 and 59 years old, and only a minority was
younger than 40 years. Half of the women in the cohort
had a low level of education (e.g., they were illiterate or
had an incomplete elementary education), and 10% had
completed a higher education level.
The adherence rate was compiled from the information
for each time frame as follows:
The mean and median follow-up periods were 1225
(SD = 631) and 1209 days, respectively. The cohort showed
a mean and median adherence of 86.3% and 94.3%, re-
spectively. If the patients with at least 80% adherence to
treatment were assumed to be adherent, the proportion
of adherent patients was 76.3%.
The group of adherent women was slightly older than
the group of non-adherent women, with mean ages of 58.0
and 56.0 years, respectively (student’s t-test, p < 0.0001).
Based on the chi-square test, we found associations of
adherence with all categorical variables except the histo-
logical primary tumor type (p = 0.6049) and laterality
(p = 0.2690; Tables 1, 2 and 3).
Table 1 presents the results according to sociodemo-
graphic variables and shows the lower likelihood of ad-
herence among younger women (<40 years). Table 1 also
shows the higher likelihood of adherence among women
who had completed second grade or higher and among
those with a partner; these factors were found to have
borderline associations.
In relation to the clinical variables (Table 2), the results
show a higher likelihood of adherence among women with
a family history of cancer and a lower likelihood of ad-
herence among women who were alcohol drinkers or
smokers. The likelihood of adherence was especially low
among those who were diagnosed with cancer at a non-
curable stage (III and IV).
With regard to the variables related to patient care
(Table 3), there was a higher likelihood of adherence in
women who were treated with TMX alone, as well as
those who underwent surgery. In contrast, women who
were treated with both types of hormone therapy (switch-
ing from 1 form of therapy to the other), who underwent
radiotherapy, who had more consultations with clinical
oncologists, or who underwent seven or more chemother-
apy procedures, hospitalizations, and tests all had a lower
likelihood of adherence. The results also revealed a lower
Table 1 Distribution of socio-demographic characteristics
according to adherence to hormone treatment
(N = 5,861)
Variable Adherent Non-adherent χ2 (p)
N % N %
Age (years) <0.0001
< 40 342 65.9 177 34.1
40 - 49 1,052 74.4 362 25.6
50 - 59 1,165 77.7 334 22.3
60 - 69 950 79.0 253 21.0
> 70 961 78.4 265 21.6
Education 0.0530
Illiterate + incomplete 1st grade 2,219 75.4 724 24.6
Complete 1st grade 772 74.8 260 25.2
2nd grade + higher education 1,444 78.5 395 21.5
No information 35 74.5 12 25.5
Relationship status at start
of treatment
0.0022
With a partner 2,135 78.3 590 21.6
Without a partner 2,307 74.5 791 25.5
No information 28 73.7 10 26.3
Table 2 Distribution of clinical characteristics according
to adherence to hormone treatment (N = 5,861)
Variable Adherent Non-adherent χ2 (p)
N % N %
Family history of cancer 0.0454
Yes 2,519 77.5 732 22.5
No 1,816 74.9 610 25.1
No information 135 73.4 49 26.6
Alcohol consumption 0.0082
Yes 1,181 73.6 424 26.4
No 3,164 77.4 924 22.6
No information 125 74.4 43 25.4
Smoker 0.0014
Yes 1,503 73.9 530 26.1
No 2,902 77.7 832 22.3




Invasive ductal carcinoma (IDC) 3,561 76.1 1117 23.9
Other tumors 909 76.8 274 23.2
Laterality 0.2690
Unilateral 4,293 76.4 1325 23.6
Bilateral 173 73.3 63 26.7
No information 4 57.1 3 42.8
Stage < 0.0001
Curable 2,742 83.4 544 16.6
Non-curable 1,549 65.3 822 34.7
No information 179 87.7 25 12.2
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consulted with a mastologist and among those who
had not received professional therapeutic support or
psychotherapy.
Table 4 shows the multiple logistic regression model
that identified the effects of the explanatory variables on
adherence to hormone therapy.
The likelihood of adherence increased with increasing
age (OR = 1.012, 95% CI = 1.006-1.018) and with the
number of psychotherapy consultations (OR = 1.055, 95%
CI = 1.025-1.086). It was greater among women with a
mid-level education (OR = 1.248, 95% CI = 1.055-1.477) or
higher education (OR = 1.362, 95% CI = 1.07-1.722), as
well as among those with a partner (OR = 1.264, 95%
CI = 1.106-1.444), those who underwent breast cancer
surgery (OR = 1.281, 95% CI = 1.120-1.466), those who
consulted with a mastologist (1–4 visits, OR = 1.524, 95%
CI = 1.220-1.904; ≥5 visits, OR = 3.598, 95% CI = 2.911-
4.447) or an oncologist (1–4 visits, OR = 1.277, 95% CI =
1.052-1.550; ≥ 5 visits, OR = 1.378; 95% CI = 1.142-1.662),
and those who underwent one or no exams (OR = 1.291,
95% CI = 1.107-1.507). On the other hand, the likelihood of
adherence was lower among patients diagnosed at a non-
curable stage (OR = 0.481, 95% CI = 0.418-0.552), those
who were alcohol drinkers (OR = 0.797, 95% CI = 0.690-
0.921), those who received chemotherapy (OR = 0.764;
95% CI = 0.651-0.897), those who had three or more hos-
pitalizations (OR = 0.587, 95% CI = 0.498-0.693) or at leastfour exams (OR = 0.720, 95% CI = 0.596-0.871), and those
who were treated with both TMX and AIS (OR = 0.730,
95% CI = 0.630-0.846).Discussion
The observed level of adherence to hormone therapy
(76.3%) in this study was consistent with those found in
other published studies, that indicated, considering the
same criteria to define adherence, proportions of 75%
[20] and 72% [22], or a mean adherence of 93% [12].
However, we underline the difficulties of correlating
some available previous studies due to differences in ad-
herence definitions, eligibility criteria (e.g., patients with
early tumors or only either young or elderly women),
analysis methods, and the types of drugs used (only
TMX, only IAS, or both).
The method employed in this study, as in others, ac-
counts for medication delivery as a proxy for medication
use, what may result in an overestimation of adherence
rates. It is a limitation, but it is believed that the bias
Table 3 Distribution of breast cancer treatment
procedures according to adherence to hormone
treatment (N = 5,861)
Variable Adherent Non-adherent χ2 (p)
N % N %
Type of hormone therapy <0.0001
TMX only 3,014 79.8 762 20.2
AIS only 256 75.5 83 24.5
Both (TMX + AIS) 1,200 68.7 546 31.3
Surgery 0.0007
Yes 2,720 77.8 775 22.2
No 1,750 74.0 616 26.0
Chemotherapy < 0.0001
Yes 2,553 72.3 978 27.7
No 1,917 82.3 413 17.7
Radiotherapy < 0.0001
Yes 2,036 73.4 736 26.5
No 2,434 78.8 655 21.2
Therapeutic combination < 0.0001
HT only 447 80.9 105 19.0
HT and surgery 762 84.8 137 15.2
HT and CT 395 68.2 184 31.8
HT and RT 405 80.5 98 19.5
HT, CT and surgery 830 78.4 229 21.6
HT, RT and surgery 303 80.6 73 19.4
HT, CT and RT 503 68.7 229 31.3
HT, CT, RT and surgery 825 71.1 336 28.9
CT frequency < 0.0001
No procedure 1,917 82.3 413 17.7
1 to 3 procedures 560 81.2 130 18.8
4 to 6 procedures 1,463 82.3 314 17.7
≥ 7procedures 530 49.8 534 50.2
Frequency of hospitalization < 0.0001
None 752 78.2 209 21.7
One 2,250 80.5 544 19.5
Two 909 76.9 273 23.1
≥ 3 559 60.5 365 39.5
Mastologist consultations < 0.0001
None 343 55.6 274 44.4
1 to 4 consultations 693 69.2 308 30.8
5 to 13 consultations 2,473 83.2 498 16.8
≥14 consultations 961 75.5 311 24.5
Clinical oncologist consultations < 0.0001
None 1,006 80.3 251 20.0
1 to 4 consultations 1,325 79.1 349 20.8
5 to 12 consultations 1,126 74.6 384 25.4
Table 3 Distribution of breast cancer treatment
procedures according to adherence to hormone
treatment (N = 5,861) (Continued)
≥13 consultations 1,013 71.3 407 28.7
Other physician consultations < 0.0001
≤ 9 consultations 410 67.9 194 32.1
10 to 22 consultations 1,683 78.0 475 22.0
23 to 34 consultations 1,316 80.5 319 19.5
≥35 consultations 1,061 72.5 403 27.5
Psychotherapy consultations < 0.0001
None 2,422 72.7 909 27.3
1 to 3 consultations 1,577 80.0 394 20.0
≥4 consultations 471 84.3 88 15.7
Therapeutic support consultations < 0.0001
None 994 70.8 410 29.2
1 to 3 consultations 1,553 77.3 457 22.7
4 to 7 consultations 872 77.2 258 22.8
≥8 consultations 1,051 79.8 266 20.2
DATS (tests) < 0.0001
None 870 78.2 242 21.8
1 test 1,587 79.1 420 20.9
2 to 3 tests 1,377 75.8 439 24.2
≥4 tests 636 68.7 290 31.3
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basis of secondary data from large populations [23].
Another limit of this study was the absence of individual
information regarding treatment side effects, which could
certainly affect hormone therapy adherence [24].
The truncation of adherence in cases where it reached
levels above 100% is justified by the awareness of situations
such as the occurrence of deaths, change of medication,
and anticipated drug deliveries to meet patient needs.
Only women who received drugs at least twice were in-
cluded in the study, once the MPR formula requires two
dispensing dates. This procedure could have contributed
to over or underestimations of the adherence rates, since
who received the medication only one time could have
been adherent or not to treatment in another place.
Moreover, we underline the difference between the
concepts of treatment adherence and persistence, indi-
cating that adherent patients may be non-persistent if
they interrupt the treatment before the recommended
period of five years.
This study was based on data from a single hospital,
and we acknowledge that this might be a limitation.
Nevertheless, it is important to emphasize that the hos-
pital allows universal access, restricting entrance only to
patients who was treated previously in other locations.
Table 4 Multiple logistic regression model for adherence to hormone treatment (N = 5,861)
Variable Coefficient Standard error Pr > χ2 Odds ratio 95% CI
Intercept −0.3642 0.2591 0.1598
Age* (years) 0.0117 0.0029 <0.0001 1.012 1.006 – 1.018
Education
High school diploma 0.2216 0.0858 0.0098 1.248 1.055 – 1.477
Bachelor’s degree 0.3087 0.1197 0.0099 1.362 1.077 - 1.722
Conjugal status - with a partner 0.2341 0.0681 0.0006 1.264 1.106 – 1.444
Disease stage - non-curable −0.7329 0.0711 <0.0001 0.481 0.418 – 0.552
Alcohol consumption (yes) −0.2266 0.0735 0.0020 0.797 0.690 – 0.921
Breast cancer surgery (yes) 0.2478 0.0686 0.0003 1.281 1.120 – 1.466
Chemotherapy (yes) −0.2686 0.0816 0.0010 0.764 0.651 – 0.897
Hospitalizations (≥3) −0.5322 0.0842 <0.0001 0.587 0.498 – 0.693
Mastologist visits
1-4 0.4215 0.1135 0.0002 1.524 1.220 – 1.904
≥ 5 1.2805 0.1081 <0.0001 3.598 2.911 – 4.447
Oncologist visits
1-4 0.2446 0.0989 0.0134 1.277 1.052 – 1.550
≥ 5 0.3203 0.0958 0.0008 1.378 1.142 – 1.662
Diagnostic and therapeutic services
≤1 exam 0.2557 0.0788 0.0012 1.291 1.107 – 1.507
≥ 4 exams −0.3284 0.0968 0.0007 0.720 0.596 – 0.871
Psychotherapy* (consultations) 0.0534 0.0147 0.0003 1.055 1.025 – 1.086
Type of hormone therapy - both (TMX + AIS) −0.3148 0.0751 <0.0001 0.730 0.630 – 0.846
CI = Confidence interval. *Continuous variables. References for categorical variables: education – incomplete high school or lower, no information; conjugal status
at start of treatment – without a partner, no information; disease stage – curable, no information; alcohol consumption – no, no information; breast cancer
surgery – no; chemotherapy – no; hospitalization – <3; mastologist consultations – none; clinical oncologist consultations – none; DTS – 2–3 exams; type of
hormone therapy - TMX only, AIS only.
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in this study agrees with some studies [12,19,21,25] yet
contradicting others [26]. It can be speculated that the
observed lower adherence rate among younger patients
is related to the adverse effects of hormone therapy on
the women’s sexuality, which include fertility issues and
menopausal symptoms [13]. Moreover, the association of
greater treatment compliance with having a partner, also
found in other studies [22,26], might be linked to sup-
port reception. This result is consistent with the idea
that social support is highly predictive of adherence [1].
In this cohort, there was greater adherence among
women with higher education levels, contrasting to
findings of Wigertz et al. [26], who did not identify a
statistically significant association between adherence
and education. Anyway, it must be noted that it is very
difficult to ensure that education in the Brazilian con-
text is comparable to that of developed countries, and
there are few other national studies on the subject. It is
plausible the observation of greater adherence among
patients with higher education while considering, amongother things, that socioeconomic status has also been
identified as predictive of adherence [21].
With regard to the disease stage, the observation of lower
compliance among patients at non-curable stages (III and
IV) contradicts Wigertz et al. [26], who found greater ad-
herence among women with larger tumors. Kimmick et al.
[20] found no association between these variables. Import-
antly, however, the majority of studies on this topic were
based only on cohorts of women with early stage disease,
which reflects the reality in developed countries, wherein
60% of tumors are diagnosed at a localized stage and thus
women who are fighting the disease are at a great advantage.
In Brazil, despite the efforts of the Ministry of Health
to implement national policies for earlier breast cancer
detection, the proportion of advanced-stage diagnoses is
very high, compared to that in developed countries [27].
The lower adherence rates among women with a non-
curable stage at diagnosis emphasize the importance of
investments in early diagnosis since it has a direct effect
on patient survival [4,8] and also an indirect effect by
facilitating treatment compliance.
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the association between both smoking and alcohol con-
sumption and lower treatment adherence [21], while the
multivariate analysis ratified only the effect of alcohol
consumption on the dependent variable.
This study reinforces the importance of surgery in breast
cancer treatment. Previously, surgery had been associated
with longer survival [27,28], and herein, it was associated
with greater patient adherence to hormone therapy. The
current study also revealed that patient monitoring by
mastologists and oncologists had a positive association ef-
fect on hormone therapy adherence [19]. However, a more
intensive use of health care resources such as chemother-
apy, exams and hospitalizations appeared to associate with
lower adherence. This result was not directly observed in
other studies but may be indirectly related to the associ-
ation between lower adherence and comorbidities, ob-
served in other studies [15,20]. Additionally, it should be
emphasized that the independent effects of these clinical
variables, even after controlling for the disease stage at
diagnosis, might reflect the different levels of tumor ag-
gressiveness, different levels of treatment responses, and
the presence of comorbidities.
Another notable finding in this study was the inde-
pendent positive effect of psychotherapy consultations
on the likelihood of treatment adherence. This result
might be related to those of studies that related psycho-
logical problems, particularly depression, to lower treat-
ment adherence [1].
For Kim & Toge [29], a multidisciplinary approach to
breast cancer treatment broke down barriers to access,
facilitated cooperation between doctors to produce bet-
ter treatment proposals, and improved the quality of
care and patient satisfaction. Although the multidisciplin-
ary team approach to oncology is required by the Brazilian
Ministry of Health [16] and is a necessary condition to
hospital certification for the provision of oncological care
in the Unified Health System (Sistema Único de Saúde;
SUS), the present study indicates that between 24.0% and
57.0% of women who were treated at INCA had no records
of multidisciplinary therapeutic support consultations or
psychotherapy, respectively. Thus, more consultations with
nurses, psychologists, social workers and physiotherapists
should be encouraged in the clinical monitoring phase.
Steps that facilitate the patient’s understanding of the need
for treatment and that promote and monitor adherence
should be valued. Multidisciplinary therapeutic support
consultations were associated with greater adherence to
hormone therapy in the bivariate analysis, but were not sig-
nificant in the multivariate model when psychotherapy
consultations were considered separately. The role of such
consultations should be further explored in other studies,
which may provide more information about their effects
and indicate potential changes in their objectives and uses.With regard to the type of hormone therapy, the poor
adherence among patients who used both TMX and AIS
has been corroborated in others studies [19,26]. This
finding might be due to the frequent musculoskeletal
toxicity associated with AIS [30]. Other studies have
found no statistically significant differences between the
different types of hormone therapy and adherence [31,32],
although a lower adherence rate has been noted for ana-
strozole than for TMX [32]. It is noteworthy that in the
current study cohort, the majority (64.4%) of the women
were treated with TMX alone, while 29.8% received a
combination of TMX and AIS and a few women (5.8%)
were treated only with AIS. The indication of each
drug according to the patient’s morbidity profile was
not analyzed.
Conclusion
In this cohort, approximately 25% of the breast cancer
patients were considered to be non-adherent to hormone
treatment, thus risking a clinical response below the ex-
pected standards. Moreover, this study identified the pa-
tient characteristics that are associated with greater
vulnerability while receiving hormone therapy for breast
cancer and reveals the health care practices that facili-
tate adherence to treatment. Interventions based on
these results may help improve patient adherence, qual-
ity of care and outcomes.
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